NCT03124433View on ClinicalTrials.gov

Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

August 22, 2019

Study Completion Date

August 22, 2019

Conditions
Cancer of the Prostate
Interventions
DRUG

Apalutamide

Participants will receive oral apalutamide 240mg daily for 12 weeks

Trial Locations (1)

169608

Department of Urology, Singapore

All Listed Sponsors
lead

Singapore General Hospital

OTHER

NCT03124433 - Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer | Biotech Hunter | Biotech Hunter